Back

Effect of 1st line treatment on aortic inflammation as assessed by 18 FDG PET/CT in patients with Hodgkin and non-Hodgkin lymphoma

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: Cardio-oncology 4 Cardio-Oncology ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Dimitrios Terentes-Printzios

National & Kapodistrian University of Athens, Athens (Greece)

6 More presentations in this session

Presentation thumbnail
Basal characteristics of the prospective spanish immunotherapy registry of cardiovascular toxicity: SIR-CVT
Doctor E. Zatarain-Nicolas (Madrid, ES)
Abstract Slides
Presentation thumbnail
The prognostic significance of troponin level in patients with malignancy (NIHR Health Informatics Collaborative TROP-MALIGNANCY study)
Doctor A. Kaura (London, GB)
Abstract Slides
Presentation thumbnail
COVID-19 and acute heart failure among patients with cancer
Doctor M. Bergami (Bologna, IT)
Abstract Slides
Presentation thumbnail
Use of emgliflozine in cardiotoxicity treatment. EMPACARD-treatment registry. Six-months follow-up
Doctor A. Daniele (Buenos Aires, AR)
Abstract Slides
Presentation thumbnail
Prognostic impact of coronary artery calcifications in patients with newly diagnosed prostate cancer
Doctor N. Stoedkilde-Joergensen (Aarhus, DK)
Abstract Slides

Access the full session

Session thumbnail
Cardio-oncology 4

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources